Literature DB >> 9745923

Genetic polymorphisms in Parkinson's disease.

H Checkoway1, F M Farin, P Costa-Mallen, S C Kirchner, L G Costa.   

Abstract

The search for genetic polymorphisms relevant to Parkinson's disease etiology and pathogenesis has been motivated by recent thinking emphasizing the potential significance of gene-environment interactions. Especially influential to this research have been the MPTP model of PD induction, hypotheses concerning oxidative stressor reactions, and epidemiological observations of an inverse relation between cigarette smoking and PD risk. This brief review summarizes trends in genetic polymorphism research, with examples provided by investigations of cytochrome P450 enzymes, monoamine oxidase, superoxide dismutase, and mitochondrial genes.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9745923

Source DB:  PubMed          Journal:  Neurotoxicology        ISSN： 0161-813X            Impact factor:   4.294


  10 in total

1.  Geographic model and biomarker-derived measures of pesticide exposure and Parkinson's disease.

Authors:  Beate Ritz; Sadie Costello
Journal:  Ann N Y Acad Sci       Date:  2006-09       Impact factor: 5.691

Review 2.  Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution.

Authors:  Massimo Stefani; Christopher M Dobson
Journal:  J Mol Med (Berl)       Date:  2003-08-27       Impact factor: 4.599

3.  Lack of the DNA repair enzyme OGG1 sensitizes dopamine neurons to manganese toxicity during development.

Authors:  Fernando Cardozo-Pelaez; David P Cox; Celeste Bolin
Journal:  Gene Expr       Date:  2005

4.  Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E epsilon4 allele as risk factors in Alzheimer's disease and in Parkinson's disease with coexisting Alzheimer pathology.

Authors:  K M Mattila; J O Rinne; M Röyttä; P Laippala; T Pietilä; H Kalimo; T Koivula; H Frey; T Lehtimäki
Journal:  J Med Genet       Date:  2000-10       Impact factor: 6.318

Review 5.  Perspectives on MAO-B in aging and neurological disease: where do we go from here?

Authors:  M Jyothi Kumar; Julie K Andersen
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590

6.  Chromosomal loci influencing the susceptibility to the parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  Marco Sedelis; Katja Hofele; Rainer K W Schwarting; Joseph P Huston; John K Belknap
Journal:  J Neurosci       Date:  2003-09-10       Impact factor: 6.167

Review 7.  Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds.

Authors:  Guillermo Gervasini; Juan Antonio Carrillo; Julio Benitez
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Altered platelet monoamine oxidase-B activity in idiopathic Parkinson's disease.

Authors:  Maroof Husain; Rakesh Shukla; Madhu Dikshit; Pradeep K Maheshwari; Devika Nag; Rikhab C Srimal; Prahlad K Seth; Vinay K Khanna
Journal:  Neurochem Res       Date:  2009-03-04       Impact factor: 3.996

Review 9.  Neurodegenerative diseases: an overview of environmental risk factors.

Authors:  Rebecca C Brown; Alan H Lockwood; Babasaheb R Sonawane
Journal:  Environ Health Perspect       Date:  2005-09       Impact factor: 9.031

10.  Polymorphisms in the Mn-SOD and EC-SOD genes and their relationship to diabetic neuropathy in type 1 diabetes mellitus.

Authors:  D A Chistyakov; K V Savost'anov; E V Zotova; V V Nosikov
Journal:  BMC Med Genet       Date:  2001-03-28       Impact factor: 2.103
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.